Dr. Lindsay Rosenwald has gained a respectable standing on Wall Street where he is a venture capitalist and hedge fund manager.  For almost two decades he has also been building an uncompromising reputation in life-sciences and medicine research.  He has always played a key role in R&D breakthroughs in biotechnology and healthcare.  As a result of the way he combines medicine with finance, Dr. Rosenwald has the expertise to both launch new initiatives in research as well as locate ideal companies to invest in.  His work has helped to extend the reaches of healthcare, indirectly benefiting millions of people the world over.  It would be difficult to find another individual who has excelled as well as he in these industries.

During his stunning career, almost two decades long, Dr. Lindsay A. Rosenwald is responsible for creating and recapitalizing numerous public and private companies in the life-science and biotech industries.

Rosenwald finished his high school education in 1973 at Abington.  Thereafter, he attended Pennsylvania State University, graduating with a degree in Finance.  After Penn State, he received his medical degree from the Temple University School of Medicine and went on to meet the requirements of his medical internship at Abington Medical Hospital.  For a short while he had his own private medical practice before moving on to other things.  He carved his way successfully through Wall Street, combining his knowledge in both medicine and finance to form new ideas.

Between the years of 1994 and 2007, Rosenwald took on the role of executive director at the Aries Funds which has invested more than $1 billion into healthcare companies that show promise.  Rosenwald also directed the Orion Fund from 2002 to 2006, which invested only in the biotech industry, especially private investments in public equity.

Dr. Rosenwald also created the Rosenwald Foundation, a non-profit that is committed to supporting scientific, healthcare and educational companies.

A unique mixture of finance and medicine has led Rosenwald down a path of discovery in the medicine, biotechnology and life sciences industries, where he has had the opportunity to explore new and innovative projects.

Today Dr. Rosenwald is a director at the Republican Jewish Coalition.  He is also the president of Paramount Group which concentrates its efforts on investment banking, R&D, and equity management in the industries of life-science and biotechnology.  One of his most recent enterprises is the OpusPoint Partners, LLC, established in 2009 with the purpose of supporting innovations in life-sciences and biotechnology.  The company is dedicated to technological breakthroughs that will influence and guide today’s life-sciences and biotechnology companies.

Some of Dr. Lindsay Rosenwald and his team’s most admirable accomplishments include the funding they have offered various companies and drug candidates showing great promise.   One such company is Cougar Biotechnology Inc., based in L.A., which focuses on cancer treatment.  One of the company’s recent developments was Abiraterone, a drug that tackles aggressive prostate cancer.  The company was sold to Johnson & Johnson for almost $1 billion in 2009 after a negotiation with Dr. Rosenwald.

It is the mandate of OpusPoint Partners and Dr. Rosenwald to continue making progress with projects like these.  With their work they intend to profoundly alter the fields of medicine and the life sciences, while giving hope to millions of people across the globe.

By creating solid relationships and building upon their past experience, Dr. Rosenwald and OpusPoint Partners will pave the way to a bright future.  They blaze ahead leaving a trail of revolutionary successes.  Dr. Rosenwald is a true leader in healthcare and biotechnology.  He has a number of firsts to his name.  He was the first to put an investment into the first obesity drug in the US market.  He was also the first to start the first stem cell company that deals with public trading.  In addition, the first public gene therapy company developed with his contribution and so did the first cancer vaccine available to the public.

The present aim for Dr. Lindsay Rosenwald and OpusPoint Partners is to create a solid network with other leaders that espouse the same values and business approaches and who are dedicating to discovering and investing in ground-breaking technologies across these fields.

With this kind of commitment, strategy and expert knowledge, OpusPoint Partners and its founders, Dr. Rosenwald and Michael S. Weiss, have a brilliant and steady path lying ahead of them.  Their investments have the ability to completely alter the way in which we manage disease.

OpusPoint Partners, founded in 2009, is only one of the biotech companies established by Michael S. Weiss and Dr. Lindsay Rosenwald.  The two men have over 40 years of experience between them in life sciences and biotech investment.  They both have a strong passion for the field of biotechnology.

Cougar Biotechnology Inc. is another company founded by Dr. Lindsay Rosenwald.  The company is based in Los Angeles and focuses on experimental drug research for cancer.  Cougar has gained some attention from researchers and investors impressed by some of its more remarkable developments of experimental drugs.   One such drug has shown promise in the treatment of late-stage prostate cancer.  For about one billion dollars, Cougar Biotech Labs was acquired by Johnson & Johnson on July 10, 2009.

OpusPoint Partners and Lindsay Rosenwald are committed to maintaining strong business associations with the biotechnology and investment communities. Practicing integrity is imperative to this goal by remaining transparent and practicing honest investment.  When companies and leaders of the industry all respect these values for good business and organization, strong alliances can be formed.

OpusPoint Partners is creating relationships with several researchers, investors and corporations that have the same goals while helping new companies to meet their priority goals.  These partnerships are part of the larger aim to offer the world new innovations that will affect how diseases are diagnosed and treated.  Along with this team, Dr. Lindsay Rosenwald and OpusPoint Partners will seek out and invest in companies promising breakthrough medical research.

Dr. Lindsay Rosenwald and OpusPoint Partners are really pushing the boundaries of biotech investing.  They are changing and improving the standards of investing.  The advice they give to biotechnical facilities is to apply well-rounded business practices and a strong set of principles.  With these applications, companies can benefit from gaining high returns without high risks.  The success of OpusPoint Partners proves that this formula works.

And Dr. Rosenwald is not new to success.  He has had a wealth of experience.  He has had over 17 years on Wall Street as a biotechnology entrepreneur.  He has also played a big role in the founding and recapitalization of several biotech and life sciences companies, both public and private.  He holds a B.S. in Finance from Pennsylvania State University and an M.D. from the Temple University School of Medicine.

He also has solid financial experience managing billions of dollars in funds.  He managed the Aries Funds from 1994 to 2007 and the Orion Fund from 2002 to 2006.  The Aries Funds have invested more than $1 billion in healthcare.  The Orion Fund, on the other hand, is completely for private biotechnology investing, particularly PIPEs.

OpusPoint Partners is founded upon a bold mission – to establish a strong network of life science and healthcare groups that are committed to honesty and integrity.  This is a rarity in today’s world where business leaders often disregard ethics in order to get desired clinical trial results and more profit.

OpusPoint Partners intends to be a diversion from that commonality.  The company has shown a great deal of integrity in dealings with shareholders, investors and employees.  And a valued approach of ethical standards is used in handling the matters of testing, manufacturing and investigating drugs.

Under Michael Weiss and Dr. Lindsay Rosenwald’s leadership, OpusPoint Partners has a promising future.  With the shared experience and knowledge both leaders possess, the company is bound to play a crucial role in revolutionizing medicine and healthcare.

It is difficult, though, to change practices that have been the basis of medical approaches for years.  It will take money, time, energy and strong commitment to keep within the guiding lines of ethics and to resist going to any means just to reap more profits.

Dr. Rosenwald, however, thinks this can be done.  As an example, he points out the achievements the company has already made.  Over the last several years, OpusPoint Partners has already surpassed projected goals while they assisted the financing of over 20 companies.  Using the best kind of practices and processes will most certainly yield rewards in drug research and finance.

Dr. Lindsay Rosenwald serves on the Board of Directors of the Republican Jewish Coalition.  He has also made strong connections with industry leaders from the biotechnology financing sector.  OpusPoint Partners looks forward to a successful future under his leadership.

OpusPoint Partners was created by Michael S. Weiss and Dr. Lindsay Rosenwald. Established in 2009, it is just one of a few companies the men have founded together devoted to the field of biotechnology. With 40 years of experience between them, Weiss and Rosenwald continue to express their love for biotechnology with biotech investment and life sciences.

Dr. Lindsay Rosenwald also created Cougar Biotechnology Inc., a company that researches experimental drugs for the treatment of cancer. The Los Angeles-based company has gained a certain reputation with the development of some promising drugs. One drug shows very good potential to help treat the late states of prostate cancer. On July 10, 2009, Cougar Biotech Labs was bought by Johnson & Johnson for about a billion dollars.

OpusPoint Partners and Lindsay Rosenwald are keen about developing strong investment and biotechnology relationships. This can be achieved by practicing integrity in relations (marked by being direct and straightforward and by investing honestly). This is not only good business ethics but is essential to the culture of an organization. When all the companies and industry leaders in partnership share in the same values, it makes their bonds more meaningful.

Lindsay Rosenwald and OpusPoint Partners are aligning with several entities – a team of individuals, researchers, investors and corporations – with the same commitments to innovative disease treatment. This alignment will also assist emerging companies in accomplishing their most important aims. With these relationships, Dr. Lindsay Rosenwald and OpusPoint Partners will locate and invest in companies doing the research on the verge of important medical discoveries.

Dr. Lindsay Rosenwald and OpusPoint Partners are pushing the limits of the biotech investment industry by asking companies to raise their current standards. Assuming higher standards of ethical approach and responsibility will allow companies to continue to earn profit without reducing the quality of production, results and other potential risks. The company’s successes have proven the effectiveness of this.

And Dr. Rosenwald is no stranger to applying successful models. He has been proactively involved in establishing and recapitalizing biotech and life sciences companies, both public and private. In addition he has spent more than 17 years as a Wall Street biotechnology entrepreneur. He obtained a B.S. in Finance from Pennsylvania State University and an M.D. from the Temple University School of Medicine.

He has also managed a variety of large investment funds. The Aries Funds, under his management from 1994 to 2007, invested more than $1 billion towards healthcare. The Orion Fund, which he managed from 2002 to 2006, is entirely geared towards private biotechnology investments, principally PIPEs.

OpusPoint Partners’ aim is to form a powerful group of connections in life science and healthcare that will uphold strong moral principles. This kind of establishment is a rare incidence in today’s money-making world. It is all too common that business leaders make choices for profit without considering their ethical implications.

OpusPoint Partners aims to go against the grain. It stands strongly committed to maintaining high ethical principles in the testing, manufacturing and investigating of drugs. It will also practice fairness and responsibility in relations with its business partners.

The future of OpusPoint Partners looks exceedingly bright under the direction of Michael Weiss and Dr. Lindsay Rosenwald. The two highly experienced leaders both know that they have a lot to offer in changing the face of medical treatment and diagnosis.

However, changing what has been steeped in years of practice cannot be easy. The process will require a great deal of devoted time, money and real dedication in order to maintain ethical commitments.

Dr. Rosenwald believes this can be achieved. In less than two years, OpusPoint Partners helped to finance more than 20 companies, reaching beyond its slated goals, a prime example of how change can happen. With the use of the right kinds of practices and processes, large returns in drug research and finance are inevitable.

Dr. Lindsay Rosenwald represents the Republican Jewish Coalition as a member of the Board of Directors. He also has several important affiliations with biotechnology industry leaders in the financing sector. OpusPoint Partners is bound to have a successful future with Dr. Rosenwald as its leader.

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.
The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.
Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

According to Dr. Johann de Bono, a lead analyst at the Institute of Cancer Research, and Dr. Lindsay Rosenwald, a leading investor in the biotechnology sector, abiraterone is “a major step forward in prostate cancer” treatment. The data of the trial were presented at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy and demonstrated a significant improvement of survival in patients undergoing the abiraterone treatment. They lived nearly four months longer than the patients who received placebo.

In many cases, prostate cancer progresses even after receiving chemotherapy, therefore it is critically important to address the needs of the patients with advanced prostate cancer. As Dr. Rosenwald and Dr. de Bono say, patients with castration-resistant prostate cancer aggravated by metastases have a very poor prognosis and have only 3 to 5 years of life after the diagnosis is set. For such men, abiraterone can prolong life.

Scientific research showed that prostate cancer depends on the level of male hormone testosterone. If this hormone is low in the body, this may reduce the growth of the tumor. However, after a long-term hormonal treatment, many prostate cancers become resistant to hormones and start growing again. This is where abiraterone acetate can help. It is specifically designed to inhibit the production of androgen in the adrenal glands, testes as well as prostate cancer itself. 1,195 patients from 13 countries participated in the Phase III trial. Most such patients were treated with one of the chemotherapeutic drugs composed of docetaxel, an anti-mitotic chemotherapy drug.

398 patients received the corticosteroid prednisone plus placebo, and they lived for about 10 months. 797 patients took abiraterone acetate plus prednisone and their survival was about 15 months.

A pre-specified interim analysis of the study demonstrated the advantages of abiraterone acetate. Because of this, the Independent Data Monitoring Committee recommended J&J’s to unblind the trial and allow the patients in the placebo group to be treated with abiraterone.

Although there are obvious benefits of the drug, there are still some unclear points about abiraterone, e.g. how to determine which patients should be treated with the drug. Obviously, this is a significant step forward, more work is required to improve the results in patients with prostate cancer.

Dr. Lindsay A. Rosenwald and his portfolio companies keep a close eye on the trial results and promote the drug by making investments in its trial and further commercialization.

Prof. Carsten Bokemeyer, director of University Cancer Center Hamburg, Germany, believes that abiraterone acetate can be a great addition to the treatment of prostate cancer.

Since patients with advanced prostate cancer have very limited treatment options, abiraterone is a good choice with low toxicity that significantly extends life. Furthermore, the results of the trial also show that patients after chemotherapy can be treated, which is very important for “the future management of castration-resistant prostate cancer.”

The acquisition of Cougar Biotechnology Inc. by Johnson & Johnson seems to be a great success leading to promising outcomes in the treatment of prostate cancer in men. Late in 2010, J&J halted its Phase III clinical trial of its novel drug candidate, abiraterone acetate, which was originally studied by the analysts and scientists at Cougar Biotechnology. It is well known that Dr. Lindsay Rosenwald, along with his team of specialists in the biotechnology sector, invested in the first trial stages of abiraterone. The first clinical trial of abiraterone showed great success and promising results; therefore Lindsay Rosenwald funded Cougar Biotechnology and promoted indirectly the development of this drug and its further acquisition by Johnson & Johnson. Because interim analysis of the Phase III demonstrated good results, it was suggested that the company revealed the data and allowed the patients treated with placebo to take abiraterone. In October, the company is going to reveal the exact numbers and the time abiraterone can prolong lives. This data will be shared at a scientific meeting, which will take place in Milan. If the drug has statistically larger survival in prostate cancer patients, this will be enough for abiraterone to get approval, given the poor prognosis for those men, who failed Taxotere treatment offered by Sanofi-Aventis.

Sanofi is going to file marketing applications for it’s another drug, Cabazitaxel. However, it is still difficult to compare the drug with abiraterone. Patients treated with Cabazitaxel lived median 15.1 months. That time the drug was compared to Novantrone, a product by OSI Pharmaceuticals and EMD Serono. J&J compared its abiraterone plus the steroid prednisone treatment to prednisone alone.

It doesn’t matter what drug hits the leading position, since it is the fact that the sales of Provenge(a drug by Dendreon) won’t be affected. The drug was developed as an aid to the immune system and is commonly used in patients with castrate-resistant prostate cancer, whose disease progressed in spite of their hormonal therapy. Both these drugs are going to be used when patients fail their Taxotere treatment. Provenge is most likely to be used in these cases, too.

Since prostate cancer is considered to be the disease, which is very difficult to treat, abiraterone may be a good option for patients. Investors, like Lindsay Rosenwald, MD, have already noticed prospects of this drug and invested in its research and development giving more survival chances to men with prostate cancer.

Johnson & Johnson reported the highest positive research returns from the analysis of abiterone treatment the previous month and declared firm intention to find the preparation’s commendation. Minute descriptions of the results, along with the numerous advantages of abiraterone treatment indisputably prolonging lives, were introduced at the ESMO annual conference.

The phase III research recruited 1,195 prostate cancer sufferers, treating them at random with abiterone acetate along with the steroid prednisone or a placebo along with prednisone. Every sufferer participating in the research had a diagnosis of metastatic, terminal stage prostate cancer with sarcomas no more beneficially affected by hormonal therapy or chemotherapy, namely the most famous and generally used preparation Taxotere.

The sufferers instituted abiraterone therapy showed 35% increase of chances to survive in comparison with the sufferers taking a placebo. The average statistics data on people surviving showed the results as follows: the sufferers treated with abiraterone survived for 14.8 months, and 10.9 of those treated with a placebo, which makes abiraterone about four months more effective in survival.

Physicians normally start prostate cancer sufferers treatment through hormonal therapy so as to cease testosterone producing and to delay sarcoma development, however many of the prostate cancers come to be refractory to such a therapy and begin growing anew.

The original research introduced at the ESMO congress and funded by leading investors, including Lindsay Rosenwald, MD, demonstrated the abiraterone usage on prostate cancer sufferers who have no more beneficial effect from hormone therapy and chemotherapy – the third line sufferers in hopeless condition. However Johnson & Johnson is researching and analyzing the effect of abiraterone usage on the sufferers who show no more beneficial effect from hormone therapy still not yet subjected to chemotherapy.

Prostate cancer immunotherapy Provenge

Aberaterone’s primary rivalry seems to have started due  Sanofi-Aventis’ (SNY) Jevtana, commended sooner current year for hopeless third line prostate cancer sufferers. In the middle of the phase III research, Jevtana demonstrated average statistics data on people surviving with treatment for 15.1 months in comparison with 12.7 months for the sufferers treated with different chemotherapy preparation mitoxantrone.

Medivation (MDVN) together with partner Astellas are working out MDV3100, a prostate cancer preparation which in its effect does not differ much from abiraterone. Phase III researches have already started.

About Abiraterone Acetate

Abiraterone has been licensed by Cougar Biotechnology and acquired by Johnson & Johnson after its phase II clinical trial for a late stage drug candidate for the treatment of prostate cancer. Cougar has been funded by several leading investors, including Dr. Lindsay Rosenwald, as a promising first-in-class compound tested in patients with advanced castrate-resistant prostate cancer, who have yet to receive their chemotherapy.

J&J filed its marketing applications in late 2010. If approved, abiraterone acetate will be allowed for distribution in early 2011 in the United States and Europe with the rest of the world to follow.

Dr. Lindsay Rosenwald knows exactly where to invest. He has a very strong opinion about how the drug is going to fare and how the market responds to it. The information about Genasense is still to come out, but there is a very big debate on the outcome of the results and its success in the market. More information can be released from the company sources by November this year. Expert analysts are of the opinion that this wonderful drug used for skin cancer treatment is expected to do well and come through the tests very soon and get the approval from FDA as soon as the middle of next year.

All said and done it is not so easy for anybody to do excellently in two different fields at a time one, which is not at all related to the other by any means. This marvelous feet being consistently achieved by Dr. Lindsay Rosenwald time and again in the fields of finances and medicine is extra ordinarily brilliant. His success record of past twenty years speaks volumes about his dexterity and versatility in these fields.

Rosenwalds group of companies being his brain child is running ahead of many other companies in taking over a number of other companies and helping the portfolio companies perform well in the research and development field is fetching a remarkable name, fame and wealth to Dr. Lindsay Rosenwald. Dr. Lindsay Rosenwald has established such an excellent pharmaceutical company that has come out with marvelous drugs to treat prostate cancer and diabetes. These drugs are certainly going to make their niche in respective areas of treatment and win the confidence of the Doctors all over the globe.

Dr. Lindsay Rosenwald being a great investor and an excellent Bio scientist is also a great humanist. He runs a trust for the development of pioneering research works in different portfolio companies. He encourages the investment in the drug discovery and is fond of newer useful molecules that can do a world of good to the medical and bio technological fields.

Dr. Lindsay Rosenwalld is of course best known for his being an investment banker and venture capitalist, but also as a hedge fund manager. His first company, has provided many smaller biotechnical companies with the needed resources to further their work and develop some of the most beneficial drugs being tested and used today. Dr. Rosenwald gives his backing to companies where he sees the most potential therefore he is being a good steward of finances while helping humanity.

Lindsay graduated from Abington High School in 1973 and went on to pursue his career in medicine at Pennsylvania State University. He was a member of the honor society for business school known as Beta Gamma Sigma while he attended. After graduating there he was awarded a Bachelors of Science in finance degree which was in 1977. Lindsay then decided to pursue his medical interests at Temple University School of Medicine. He graduated there with a medical degree in 1983.

Deciding to begin his medical career, Dr. Lindsay Rosenwald enrolled for an internship at Abington Hospital and following that moved into private practice until 1986. It was then that he made a move that would seem outlandish to some, he went to Wall Street to become an analyst as well as physician.

By 1991 Dr. Rosenwald had now formed his group, in which he also had his first company. They provide funding to companies in the biotechnology sector that are looking to develop treatment options that are breakthrough in nature,that includes helping with their start ups and research for development.